title: [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a report of 12 patients].
abstract: OBJECTIVE
  To retrospectively review the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML).
  
  
  METHODS
  The engraftment, graft versus host disease (GVHD), infection, relapse and survival of 12 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed.
  
  
  RESULTS
  Twelve (7 males and 5 females) CMML patients with a median age of 39 years old received allo-HSCT including 7 from HLA-matched sibling and 5 from haploidentical related donors. All 12 patients achieved engraftment. The median time of neutrophil engraftment and platelet engraftment were 15 (11 - 20) days and 13 (11 - 18) days, respectively. 4 patients occurred acute GVHD, and 3 occurred chronic GVHD. After the median follow-up of 17.5 months (12 - 32 months), the overall survival, disease free survival and relapse rate were 66.7%, 66.7%, and 16.7%, respectively.
  
  
  CONCLUSIONS
  Allo-HSCT can improve the survival of patients with CMML, and is a effective therapy for CMML.
authors.affiliation: Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Lab of HSCT, Beijing 100044, China.
authors.forename: Yu-qian
authors.initials: YQ
authors.lastname: Sun
authors.forename: Lan-ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Dai-hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Feng-rong
authors.initials: FR
authors.lastname: Wang
authors.forename: Jing-zhi
authors.initials: JZ
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Chen
authors.forename: Kai-yan
authors.initials: KY
authors.lastname: Liu
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous; D055815:Young Adult